Source: Eur Respir J 2014; 44: 811-815
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Esposito Susanna, D’Ambrosio Lia, Tadolini Marina, Schaaf H. Simon, Caminero Luna Josè, Marais Ben, Centis Rosella, Dara Masoud, Matteelli Alberto, Blasi Francesco, Migliori Giovanni Battista. ERS/WHO Tuberculosis Consilium assistance with extensively drug-resistant tuberculosis management in a child: case study of compassionate delamanid use. Eur Respir J 2014; 44: 811-815

Member's Comments

No comment yet.

Related content which might interest you: WHO guidelines for the programmatic management of drug-resistant tuberculosis: 2011 update Source: Eur Respir J 2011; 38: 516-528 Year: 2011 ERS/WHO Tuberculosis Consilium assistance in extensively drug-resistant tuberculosis Source: Eur Respir J 2015; 45: 294-295 Year: 2015 Impact of social support programme on MDR-TB patients' treatment outcomes Source: International Congress 2014 – Tuberculosis: from epidemiology to therapy 3 Year: 2014 Effectiveness and safety of meropenem/clavulanate-containing regimens in the treatment of multidrug-resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Cost-effectiveness of adding novel or group 5 interventions to a background regimen for the treatment of multidrug-resistant tuberculosis in Germany Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Compassionate use of new drugs in children and adolescents with multidrug-resistant and extensively drug-resistant tuberculosis: early experiences and challenges Source: Eur Respir J 2016; 48: 938-943 Year: 2016 Active drug-safety monitoring and management for tuberculosis patients treated with bedaquiline and linezolid, Belarus – 2014-2016 Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Frequency of rifampicin resistance in re-treatment cases of pulmonary tuberculosis using Gene-Xpert in a tertiary care hospital tuberculosis clinic Source: International Congress 2015 – WHO guidelines in TB and clinical practice Year: 2015 Prospects for early implementation of ambulatory treatment in XDR TB patients by optimizing the administration of linezolid at the intensive phase of chemotherapy Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Effectiveness of mandatory treatment for tuberculosis - An observational registry study Source: Annual Congress 2013 –Epidemiological and public health features of tuberculosis Year: 2013 Extensively drug-resistant tuberculosis: early access to bedaquiline for a UK patient Source: Eur Respir J 2014; 43: 292-294 Year: 2004 Evaluation of failures treated with linezolid-containing regimen for extensively drug-resistant tuberculosis (XDR-TB) Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 HIV co-infection excludes many drug-resistant tuberculosis patients from clinical trials with novel antituberculosis drugs Source: International Congress 2015 – TB treatment: new drugs and drug resistance Year: 2015 Treatment outcomes among multidrug-resistant tuberculosis (MDR-TB) cases at a referral hospital of infectious diseases in Italy Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016 Study of prevalence of drug resistance in tuberculosis (TB) patients attending a tertiary care hospital at Mumbai Source: International Congress 2016 – Epidemiological insights into tuberculosis pathogenesis Year: 2016 MDR-TB guidelines: what is new on clinical management Source: ERS Webinar 2020: MDR-TB guidelines: what is new on clinical management Year: 2020 Compassionate use of delamanid in adults and children for drug-resistant tuberculosis: 5-year update Source: Eur Respir J, 57 (5) 2002483; 10.1183/13993003.02483-2020 Year: 2021 Clinical experience of clofazimine in the treatment of MDR-TB Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013 Estimating costs for treating patients with multi-drug resistant tuberculosis (MDR TB) under the regional tuberculosis control program, Tomsk (Russia) Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015 Current status of fluoroquinolone use for treatment of tuberculosis in Korea Source: Annual Congress 2013 –Drug-resistant tuberculosis Year: 2013